Hair Regenerative Medicine

In a world in which individual values are rapidly diversifying, Shiseido has been committed to supporting the realization of unique beauty through research on hair regenerative medicine to broaden the options for people with thinning hair and improve the quality of life of each individual. The company has extended the research area to regenerative medicine with the goal of contributing to the realization of its corporate mission, “BEAUTY INNOVATIONS FOR A BETTER WORLD.”

Shiseido has been developing hair growth agents and hair-care products ever since it initiated hair research in the 1980s. It started the research on hair regenerative medicine using the dermal sheath cup cells located in the deepest part of the hair tissues in 2016, ahead of other organizations. In collaboration with Tokyo Medical University Hospital and Toho University Ohashi Medical Center, the company initiated clinical studies to verify the safety of the use of a specified cell processing product (S-DSC®), which was produced with a unique technology developed by Shiseido, in hair regenerative therapy and to identify its optimum cell concentration. After 2020, when Kyorin University Hospital joined the research, the company conducted clinical studies at these three facilities by extensively and repeatedly injecting S-DSC® into the scalps of study participants. These studies demonstrated the efficacy and safety of S-DSC® in male and female patients with pattern baldness.

The technology developed through these joint studies has been used in S-DSC® therapy for thinning hair, which some medical facilities started to provide in 2024. Shiseido is responsible for controlling and supervising the handling of S-DSC®, including its transport, culture, and cryopreservation, according to the instructions of medical facilities.